We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 27, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Home Depot, Inc. (HD - Free Report) , salesforce.com, inc. (CRM - Free Report) , Pfizer Inc. (PFE - Free Report) , Sony Group Corporation (SONY - Free Report) and Zoetis Inc. (ZTS - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Home Depot, salesforce and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, salesforce.com, and Pfizer. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Home Depot have modestly outperformed the Zacks Retail Building Products industry over the past year (+28.5% vs. +25.8%). The Zacks analyst acknowledges the fact that the One Home Depot plan, which focuses on expanding supply chain, technology investments and digital enhancements has proved to be greatly beneficial for the company.
Steady growth in Pro and DIY customer categories is another major catalyst for growth. It has also been effectively adapting to the demand for renovations and construction activities, driven by prudent investments. Increased penetration of lumber products and continued pressure from higher transportation costs are major concerns though. The company also witnessed year-over-year moderation in its comparable store sales growth in second-quarter fiscal 2021.
salesforce shares have gained +37% in the last six months against the Zacks Computer Software industry's gain of +29.4%. The Zacks analyst believes that diverse cloud offerings, clientele strength, strategic acquisitions and partnerships have been driving the company's growth.
salesforce's sustained focus on introducing more aligned products and continued deal wins in the international market have been boosting its top line. Slack's acquisition is also likely to position the company as a leader in the enterprise team collaboration solution space. Cut-throat competition, currency fluctuations and increased spending on international expansions and data centers have been weighing on the company's near-term prospects though.
Shares of Pfizer have gained +14.3% in the past three months against the Zacks Large-Cap Pharmaceuticals industry's gain of +1.9%. The Zacks analyst believes that its sustainable pipeline with multiple late-stage programs is likely to drive growth.
Its COVID-19 vaccine candidate has now been approved for emergency use in several countries, thereby becoming a key contributor to the top line. The Consumer Healthcare JV with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Currency headwinds and pricing pressure, however, remain as major headwinds.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis
For Immediate Release
Chicago, IL – September 27, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Home Depot, Inc. (HD - Free Report) , salesforce.com, inc. (CRM - Free Report) , Pfizer Inc. (PFE - Free Report) , Sony Group Corporation (SONY - Free Report) and Zoetis Inc. (ZTS - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Home Depot, salesforce and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, salesforce.com, and Pfizer. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Home Depot have modestly outperformed the Zacks Retail Building Products industry over the past year (+28.5% vs. +25.8%). The Zacks analyst acknowledges the fact that the One Home Depot plan, which focuses on expanding supply chain, technology investments and digital enhancements has proved to be greatly beneficial for the company.
Steady growth in Pro and DIY customer categories is another major catalyst for growth. It has also been effectively adapting to the demand for renovations and construction activities, driven by prudent investments. Increased penetration of lumber products and continued pressure from higher transportation costs are major concerns though. The company also witnessed year-over-year moderation in its comparable store sales growth in second-quarter fiscal 2021.
(You can read the full research report on Home Depot here >>>)
salesforce shares have gained +37% in the last six months against the Zacks Computer Software industry's gain of +29.4%. The Zacks analyst believes that diverse cloud offerings, clientele strength, strategic acquisitions and partnerships have been driving the company's growth.
salesforce's sustained focus on introducing more aligned products and continued deal wins in the international market have been boosting its top line. Slack's acquisition is also likely to position the company as a leader in the enterprise team collaboration solution space. Cut-throat competition, currency fluctuations and increased spending on international expansions and data centers have been weighing on the company's near-term prospects though.
(You can read the full research report on salesforce here >>>)
Shares of Pfizer have gained +14.3% in the past three months against the Zacks Large-Cap Pharmaceuticals industry's gain of +1.9%. The Zacks analyst believes that its sustainable pipeline with multiple late-stage programs is likely to drive growth.
Its COVID-19 vaccine candidate has now been approved for emergency use in several countries, thereby becoming a key contributor to the top line. The Consumer Healthcare JV with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Currency headwinds and pricing pressure, however, remain as major headwinds.
(You can read the full research report on Pfizer here >>>)
Other noteworthy reports we are featuring today include Sony Group Corp. and Zoetis.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.